Pain Management IN Cancer AND Chronic Disease

The answer first

Pain Management in Cancer and Chronic Disease is the structured, mechanism-based assessment and treatment of persistent pain where the goal is functional restoration and dignity, not simply analgesia. ^[1] The answer-first approach is to classify the pain by mechanism (nociceptive somatic, visceral, or neuropathic), by temporal pattern (baseline continuous, incident, breakthrough, or end-of-dose failure), and by severity, then deploy the World Health Organization analgesic ladder in sequence while reserving adjuvants and interventional techniques for the predictable minority who fail first-line therapy. ^{[1] [4]}

For the FRACP candidate, the cancer pain long case rewards a one-sentence synthesis that names the disease, the pain mechanism, and the current regimen, a prioritised problem list distinguishing reversible causes from opioid tolerance, and an integrated plan that names the specific drug, dose, route, titration schedule, and the non-pharmacological adjuncts. ^{[1] [14]}

References14ShowHide

1. [1]Kaasa S Is Cancer Pain Control Improved by a Simple WHO Pain Analgesic Ladder Approach Combined With Tumor-Directed Treatment? J Clin Oncol, 2016.PMID 26644525
2. [2]Bandieri E, Romero M, Ripamonti CI, et al. Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain J Clin Oncol, 2016.PMID 26644526
3. [3]Wiffen PJ, McQuay HJ Oral morphine for cancer pain Cochrane Database Syst Rev, 2007.PMID 17943804
4. [4]Wiffen PJ, Wee B, Derry S, et al. Opioids for cancer pain - an overview of Cochrane reviews Cochrane Database Syst Rev, 2017.PMID 28683172
5. [5]Tassinari D, Drudi F, Rosati M, et al. The second step of the analgesic ladder and oral tramadol in the treatment of mild to moderate cancer pain: a systematic review Palliat Med, 2011.PMID 21708849
6. [6]Muijsers RB, Wagstaff AJ Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control Drugs, 2001.PMID 11772140
7. [7]Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR) Pain, 2001.PMID 11240084
8. [8]Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis Lancet Neurol, 2015.PMID 25575710
9. [9]Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group J Clin Oncol, 2004.PMID 15254060
10. [10]Nicholson AB, Watson GR, Derry S, et al. Methadone for cancer pain Cochrane Database Syst Rev, 2017.PMID 28177515
11. [11]Davis MP, Davies A, McPherson ML, et al. Opioid conversion in adults with cancer: MASCC-ASCO-AAHPM-HPNA-NICSO guideline Support Care Cancer, 2025.PMID 40029420
12. [12]Jakob T, Tesfamariam YM, Macherey S, et al. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis Cochrane Database Syst Rev, 2020.PMID 33270906
13. [13]Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials Eur J Cancer, 2012.PMID 22975218
14. [14]Dowell D, Ragan KR, Jones CM, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 MMWR Recomm Rep, 2022.PMID 36327391